TY - JOUR
T1 - Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins
AU - Rollason, Victoria
AU - Mouterde, Médéric
AU - Daali, Youssef
AU - Čížková, Martina
AU - Priehodová, Edita
AU - Kulichová, Iva
AU - Posová, Helena
AU - Petanová, Jitka
AU - Mulugeta, Anwar
AU - Makonnen, Eyasu
AU - Al-Habsi, Abir
AU - Davidson, Robin
AU - Al-Balushi, Khalid K.
AU - Al-Thihli, Khalid
AU - Cerná, Marie
AU - Al-Yahyaee, Said
AU - Černý, Viktor
AU - Yimer, Getnet
AU - Poloni, Estella S.
AU - Desmeules, Jules
N1 - Funding Information:
This study was supported by Swiss National Science Foundation grant no. 320030 to Estella S. Poloni. Médéric Mouterde is supported by the iGE3 PhD salary award.
Funding Information:
Open access funding provided by University of Geneva. We thank all ethics committees for their dedicated attention, and we express our gratitude to all volunteers, as well as to all the persons who assisted us in the implementation of the trial in the three countries, for their invaluable help. We also thank J. Chabert (Clinical Investigation Unit, Clinical Research Centre, University Hospital and Faculty of Medicine, Geneva, Switzerland) and J. D?glon for technical assistance.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Introduction and Objective: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations. Materials and Methods: The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes’ concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. Results: A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. Conclusions: In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.
AB - Introduction and Objective: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations. Materials and Methods: The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes’ concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. Results: A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. Conclusions: In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.
UR - http://www.scopus.com/inward/record.url?scp=85089908800&partnerID=8YFLogxK
U2 - 10.1007/s40264-020-00983-8
DO - 10.1007/s40264-020-00983-8
M3 - Article
C2 - 32851583
AN - SCOPUS:85089908800
SN - 0114-5916
VL - 43
SP - 1181
EP - 1189
JO - Drug Safety
JF - Drug Safety
IS - 11
ER -